Skip to content
2000
Volume 5, Issue 2
  • ISSN: 1573-4072
  • E-ISSN: 1875-6646

Abstract

The enzyme reverse transcriptase (RT) is essential in the replication of human immunodeficiency virus (HIV). Non-nucleoside reverse transcriptase inhibitors or NNRTI's are a promising class of anti-HIV drugs, which block the chemical step of DNA polymerization reaction by binding at the allosteric site of RT, leading to a viral suppression. A major limitation to the success of therapy with NNRTIs is the rapid development of drug-resistant mutants. In this work we have used molecular modeling, virtual screening, flexible docking, molecular interaction field, pharmacophoric alignment, toxicology predictions, and molecular dynamics simulations in order to design new molecules with potential higher selectivity and enzymatic inhibitory activity over K103N RT enzyme, which is the most common mutation to emerge.

Loading

Article metrics loading...

/content/journals/cbc/10.2174/157340709788452028
2009-06-01
2025-10-22
Loading full text...

Full text loading...

/content/journals/cbc/10.2174/157340709788452028
Loading

  • Article Type:
    Research Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test